drugset / Trial / NCT02076646
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
Timeline
- Start
- 2013-07-31
- Primary completion
- 2016-05-17
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Darleukin | Protein / enzyme biologic | 480000 iu/kg | — |
| Subject | Darleukin | Protein / enzyme biologic | 640000 iu/kg | — |
| Subject | Darleukin | Protein / enzyme biologic | 800000 iu/kg | — |